CureVac (NASDAQ:CVAC – Get Free Report) and Valneva (NASDAQ:VALN – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for CureVac and Valneva, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CureVac | 1 | 0 | 0 | 0 | 1.00 |
| Valneva | 2 | 0 | 1 | 0 | 1.67 |
Valneva has a consensus target price of $9.30, suggesting a potential upside of 80.23%. Given Valneva’s stronger consensus rating and higher possible upside, analysts clearly believe Valneva is more favorable than CureVac.
Profitability
This table compares CureVac and Valneva’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CureVac | 199.92% | -23.03% | -19.09% |
| Valneva | -110.33% | -153.20% | -39.50% |
Valuation & Earnings
This table compares CureVac and Valneva”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CureVac | $70.74 million | 14.78 | $175.50 million | $0.72 | 6.47 |
| Valneva | $142.94 million | 3.44 | -$130.33 million | ($2.11) | -2.45 |
CureVac has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.
Insider & Institutional Ownership
17.3% of CureVac shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 2.1% of CureVac shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
CureVac beats Valneva on 9 of the 14 factors compared between the two stocks.
About CureVac
CureVac is a biotechnology company founded in 2000 and headquartered in Tübingen, Germany. It focuses on messenger RNA (mRNA) technology, which uses genetic instructions to prompt cells to produce proteins that may help prevent or treat disease. The company has developed mRNA-based vaccine and therapeutic candidates for infectious diseases and cancer. Its programs have included COVID-19 vaccines and oncology research, and it has worked with pharmaceutical partners, including GSK, on mRNA vaccine development.
About Valneva
Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners. Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
